WST Stock Analysis
NYQ · Healthcare · Medical Instruments & Supplies
$376.00
+5.56 (+1.50%)
WST Interactive Price Chart & Trading Signals
WST Stock Snapshot — Valuation, Risk & Technical Signals
WST Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$26.46B
P/E Ratio
48.08
Forward P/E
37.66
PEG Ratio
2.88
P/B Ratio
8.85
EPS
$7.82
Dividend Yield
0.24%
52W Range
$223.83 – $386.00
Beta
1.14
Volume
0.2M
ROE
19.1%
Profit Margin
17.0%
Revenue Growth
13.8%
Gross Margin
36.8%
EV/EBITDA
28.45
Analyst Target
$407.56
The trailing price-to-earnings ratio stands at 48.1x. Forward P/E of 37.7x implies earnings expansion expected. Price-to-book is 8.85x. EV/EBITDA sits at 28.45x. Market capitalization is $26.46B. Revenue is growing at 13.8% on a trailing basis. Earnings are expanding at 18.1%. Profit margins are 17.0%. Return on equity is 19.1%. Beta of 1.14 indicates market-average volatility.
Analyst Consensus
Recommendation
Strong Buy
Low Target
$340.00
Mean Target
$407.56
High Target
$459.00
Based on 16 analysts
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
WST Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
West Pharmaceutical Services, Inc. (WST) trades above our multi-model fair value estimate of $153.42 by approximately 59.2%. Trailing P/E: 48.1x. Profitability signals include profit margin of 17.0% and return on equity of 19.1%. Recent growth metrics show revenue growth of 13.8% and earnings growth of 18.1%. Risk profile: beta of 1.14. Consensus: strong_buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 48.1x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 13.8%
Revenue is outpacing the market.
Valuation Snapshot
West Pharmaceutical Services, Inc. (WST) trades above our multi-model fair value estimate of $153.42 by approximately 59.2%. The trailing price-to-earnings ratio stands at 48.1x. Forward P/E of 37.7x suggests earnings compression ahead. Price-to-sales is 8.0x. Price-to-book is 8.9x. EV/EBITDA sits at 28.4x. Market capitalization is $26.46B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 13.8% on a trailing basis. Earnings are expanding at 18.1%. Profit margins are 17.0%. Return on equity is 19.1%. Return on assets is 11.4%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 1.14 indicates market-average volatility. Net debt position is $-119300000.00.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $407.56 implies 8.4% upside. Target range spans $340.00 to $459.00. 16 analysts cover the stock. Consensus recommendation: strong_buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
WST Overvalued
West Pharmaceutical Services, Inc. (WST) trades above our multi-model fair value estimate of $153.42 by approximately 59.2%.
Frequently Asked Questions
ValuationIs WST stock overvalued right now?
ValuationWhat is WST fair value based on current fundamentals?
RiskHow risky is WST compared with other stocks?
GrowthIs WST still growing?
AnalystWhat do analysts think about WST?
DividendDoes WST pay a dividend?
CatalystWhat could change the investment case for WST?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.